华西口腔医学杂志

• 专栏论著 • 上一篇    下一篇

抗人血管内皮生长因子单克隆抗体对荷人颊癌裸鼠血清中血管内皮生长因子水平的影响

房思炼1,王大章2,张静仪3,郑光勇2,杨西川2   

  1. 1.中山大学附属五医院 口腔颌面外科,广东 珠海519000;2.四川大学华西口腔医学院 口腔颌面外科学教研室; 3.口腔生物医学工程教育部重点实验室,四川大学,四川 成都610041
  • 收稿日期:2004-08-25 修回日期:2004-08-25 出版日期:2004-08-20 发布日期:2004-08-20
  • 通讯作者: 王大章,Tel: 028-85501943
  • 作者简介:房思炼(1970-),男,广东人,副主任医师,博士
  • 基金资助:
    国家自然科学基金资助项目(395707687,39970798)

Effect of Anti-human VEGF Monoconal Antibody on VEGF Level in Serum of Nude Mice Transplanted Buccal Carcino- ma: a Quantitative Study

FANGSi-lian1,WANGDa-zhang2,ZHANGJing-yi3,ZHENGGuang-yong2,YANGXi-chuan2   

  1. 1. Dept.ofOral and Maxillofacial Surgery,the Fifth AffiliatedHospital,Sun Yat-Sen University,Zhuhai519000,China; 2.Dept. ofOral andMaxillofacial Surgery,West China College ofStomatology,Sichuan University,Chengdu610041,China;3.Key. Laboratory ofOral Biomedical EngineeringMinistry ofEducation,Sichuan University,Chengdu610041,China
  • Received:2004-08-25 Revised:2004-08-25 Online:2004-08-20 Published:2004-08-20

摘要:

目的 定量测定抗人血管内皮生长因子(VEGF)单抗E11组、生理盐水组荷人颊癌裸鼠血清中VEGF含量并进行比较,以观察E11对体内可溶性VEGF水平的影响。方法 接种人颊鳞癌的BALB/c裸小鼠分别通过腹腔或瘤周皮下注射E11或生理盐水。接种后第18天处死,收集裸鼠血清,采用改进的间接ELISA法定量测定VEGF含量。结果 E11组裸鼠血清中VEGF含量均显著低于生理盐水组,其中E11瘤周皮下组VEGF水平最低,仅(1·17± 0·13)μg/L。结论 抗人VEGF单抗是通过中和VEGF而阻断其发挥促肿瘤血管生成的作用,从而产生抑瘤效应。荷人颊癌裸鼠血清中VEGF的水平与其荷瘤的瘤重呈正相关关系,提示恶性肿瘤患者血清中的VEGF是新的肿瘤标志物。

关键词: 血管内皮生长因子, 单克隆抗体, 酶联免疫吸附实验

Abstract:

Objective Quantitative study of the effect of anti-human VEGF mAb E11to VEGF level in serum of nude mice transplanted buccal carcinoma.Methods E11was administered into BALB/c nu/nu mice which were transplanted human buccal carcinoma. The saline was administrated as negative control. Mice were killed at 18 days. The VEGF level in serum of mice was determined by improved indirect ELSIA.Results Comparedwiththe VEGF level in serum ofmice in saline group, itwas dramat- ically decrease in E11group. The VEGF level in serum of mice treated E11by subcutaneouswas lowest and only reached (1.17± 0.13)μg/L.Conclusion It demonstrated that the anti-human VEGF mAb could reduce the VEGF level in serum by binding VEGF, and block its biological activity. It indicates that VEGF in serum of malignant tumor patient is a new tumor marker.

Key words: vascular endothelial growth factor, monoclonal antibody, enzyme-linked immunosorbent assay